Here We Go Again: Biden Administration Buys Millions of Doses of Monkeypox Vaccine After Case is Confirmed in Massachusetts – Health Officials Currently Investigating Second Potential Case in NYC
With midterms fast approaching, Democrat approval ratings cratering out of control, the hysteria surrounding Covid-19 rapidly waning, it seemed like it was only a matter of time before another crisis developed that would help the Left reinstitute the tyrannical control mechanisms they used throughout the China-virus pandemic.
Well,now we have monkeypox – a viral infection that is traditionally mild and rare in humans – popping up all across the Western countries. Oddly enough, the virus is seemingly spreading from person to person like never before, leaving many people, including those in the scientific community, scratching their heads and asking themselves: ‘what is going on?’
Now, we are obviously a long way off from what we experienced with the last pandemic, but, either way – whether the origins of this more transmissible monkeypox virus are natural, or something else (like Covid-19, Wuhan, etc.) – the timing of this new outbreak is curious – to say the least.
With a recent surge of nearly 40 cases in Europe, the first positive case being confirmed in the US on Wednesday in Massachusetts, and a second potential case now being investigated by health officials in New York City, the Biden administration is wasting no time in ‘preparing’ for the next public health emergency.
On Thursday, the Federal government ordered 13 million monkeypox vaccines from the European biotechnology company Bavarian-Nordic, according to Newsweek. In all, a total of $119 million was spent on the ‘Jynneos’ vaccines, which works out to about $9.15 per dose.
US buys millions of Monkeypox vaccines after Massachusetts confirms case https://t.co/iSIPYJEJ0Kpic.twitter.com/OkLNl1Ghk8
— New York Post (@nypost) May 19, 2022
“The order amounts to a $119 million order for Jynneos vaccines, which are used for the prevention of both smallpox and monkeypox. It was announced by biotechnology company Bavarian Nordic, which makes the vaccine, on Wednesday.
The order will convert bulk vaccines, which have already been made and invoiced under previous contracts with the U.S. government, into freeze-dried versions which have an improved shelf-life.”
A press release announcing the sale by Bavarian-Nordic clarified some of the specifics of the purchase agreement with the U.S. Biomedical Advanced Research and Development Authority (BARDA), which is part of the U.S. Department of Health and Human Services. According to their announcement, the agency had “exercised the first options under the contract
Source: The Gateway Pundit